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FK 506: An Effective Immunosuppressant for Islet Xenotransplantation 
W.J. Tze, J. Tai, S-S.C. Cheung, C. Ricordi, and T.E. Starzl 
REPLACING the damaged insulin-producing tissue by transplantation of pancreatic islets is considered the 
most physiological approach to diabetes treatment and has 
the potential to prevent the development of chronic com-
plications. Due to the large number of potential diabetic 
recipients. it would be impossible to obtain sufficient 
supply of donor organs to fulfill the demands. One solution 
to resolve donor organ shortage is the use of xenogeneic 
pancreatic islets. FK 506. a new immunosuppressive 
agent. is very effective in rat islet allotransplantation 
across the major histocompatibility (MHC) barrier. 1.1 Use 
of this agent in islet xenotransplantation has not been 
studied extensively. 
The present study was conducted to determine the 
efficacy of FK 506 on the survival of human islet xenograft 
in discordant rats. 
MATERIALS AND METHODS 
Human Islets 
Human islets were isolated from a 12-year-old donor with the 
automated digestion-filtration methods as described earlier.' Is· 
lets were then purified with Euro-Collins FicoH gradient in a Cobe 
2991 ceil separator. Purified islets were placed in culture medium 
and transponed from Pittsburgh to Vancouver for xenotransplan· 
tation. 
Transplantation and Immunosuppression 
~ale ACI rats (Harlan Sprague.Dawley. Indianapolis. Ind) of 200 
to 225 g body weight were used as recipients. Human islets stained 
with dithizone were hand·pickedunder dissection microscope. A 
total of nine rats were transplanted with 500 human islets each 
under the left renal capsule. Five transplanted rats received FK 
506 (Fujisawa Pharmaceutical Co. Osaka. Japan) treatment at 2 
mglkg!d intramuscularly for 2 weeks and then at weekly intervals 
until they were killed. startinl! immediately after transplantation. 
The remaining four rats received saline injection. 
Immunohistochemical Study 
Rat reCipients of human islet xenografts treated with FK .506 were 
killed on days 16.36.74, 100. and 124 after transplantation. Equal 
halves of the kidney containinl! the I!raft were snap frozen in LN2 
or fixed in Bouin's fixative. Paraffin sections were stained for 
insulin. glucagon. and somatostatin with immunoperoxidase stain-
ing (ABC stainiDl! kit. VectastaUl. Dimension Laboratories. Mis· 
~fssaugaK Ontario/; frozen secuons were stained for cellular 1IUlI'k. 
ers with monoclonal antibodies against rat leukocyte common 
antigen. endothelial cell (OX43), class II MHC antigen. and CD4 
and CDS lymphocyte subsets (Cedariane Laboratories. Hornby. 
Ontario I. 
Perfusion 
The kidneys containing the islet I!rBft for 36. 74, and 100 days were 
perfused in vitro to assess the function of the islets before beiDl! 
processed for immunohistochemistry. The ammal was anesthe-
tized with halothane. The abdominal cavity was opened and the 
renal anery cannulated with a PE60 catheter according to the 
method of Korsgren et a1: The cannulated kidney was removed 
and placed in a moist chamber at 31'C. the catheter connected to 
a peristaltic pump. and the organ perfused at 0.1 mUmin with 
31'C MI99 supplemented with 2.5 mmollL HEPES and 0.4% 
bovine serum albumin and continuously gassed with .5% CO:zl9S% 
0z- The experiment started with 60 minutes of perfusion with a 
medium containing 100 mgldL glucose followed by a ~minute 
perfusion with medium containing 450 mgldL glucose. and finally 
60 minutes with medium containing 100 mgldL glucose. The 
samples collected were stored at - 2O"C until insulin assay by 
radioimmunoassay (Pharmacia RIA kit. Pharmacia. Montreal. 
Quebec). The I!rBft site was divided for histology as described 
earlier. 
RESULTS 
In nonimmunosuppressed rats. by day 5 after xenotrans· 
plantation nearly all the insulin-containing cells had disap-
peared and the bulk of the graft was replaced by fibrotic 
tissue. Some of the ductal clements were still detected and 
nonnal in appearance. CD4 and CD8 T·cell subsets had 
infiltrated the graft tissue. 
The transplanted kidney with human islet graft removed 
from an FK 506-treated recipient 16 days after xenotrans· 
plantation contained human islets that appeared healthy 
and well vascularized by the host. Insulin-containing cells 
were present in abundance. In some areas occasional 
lymphoid cells were seen. 
Figure 1 shows that the human islet xenograft still 
contained insulin after 124 days in the xenogeneic rat 
recipient. The general appearance of the human islets was 
similar to that of the l6-day specimen. Again. the amount 
of lymphoid cells in the vicinity of the graft varied with the 
location. Although both CD4 and CDS cells were present 
around the graft. they were rarely seen within the islets. 
Figure 2 shows that the human islets that had survived in 
xenogeneic recipients responded to glucose stimulation 
when perfused in situ in the graft bed. Although insulin 
secretion after glucose challenge was delayed. a distinct 
increase of insulin response was detected. In contrast. no 
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fig 1. An area of human Islet xenograft tissue 124 days after 
xenotransplantallon under the kidney capsule of an FK 506 (2 
mgIkgId for 2 weeks then weekly IM)-treated ACI rat. Lymphoid 
cells of both C04 and COO subsets are present in the vicinity of the 
graft. but not within the islets (x 560). 
insulin was detected in the perfusates from normal control 
kidneys without islet trnnsplant. 
DISCUSSION 
In an earlier report we demonstrated that FK 506 was 
effective in the prolongation of fresh rat islet allograft 
across the MHC barrier.! The present findings confirmed 
that this drug was effective for the marked prolongation of 
human islet xenognft survival in rat recipients. Despite 
the presence of lymphoid cell infiltration in some areas, the 
gnft tissues appeared to be healthy and contained cells 
with demonstrable insulin and glucagon by immunohisto-
chemical stainings up to >4 months after transplantation, 
when the experiment was terminated. These human islets 
were also found to be functional as demonstrated by 
significant insulin response to glucose stimulation in two 
thirds of the cases. Histologic examination of the graft that 
did not respond to glucose challenge had many fewer islets 
in the graft bed than the others, and may account for the 
poor results. 
The important finding of this study is that FK 506 alone 
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FIg 2. Insulin concentrallona in ellluent medium collected from 
hLman islet-bearing kIdneya of FK 506-Immunosuppressed ACI 
ra1L KIdneys were perfused with medium containing 100 or 450 
rl'9'dL glucose as indicated. E~-~F 36 days; (0-0) 1()O.(jay 
xenograft, E~K mean of n = 4) c:on1rOl kidney without graft 
tissue. The human islets responded to glucose stimulation. In 
contrast. no Insulin was detected In the perfusates from normal 
con1rOI kidneys withoUt islet transplant. 
and given intermittently was effective in the islet prolon-
gation in this discordant xenograft model. In most discor-
dant islet xenograft transplantation models. the tissues 
were rapidly rejected. '.6 The present findings support the 
view that with the use of a new generation of immunosup-
pressive agents. islet xenotrnnsplantation in humans is a 
future possibility. 
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